Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

Ceptur Therapeutics, a US-based targeted oligonucleotide therapeutics developer based on research at Rutgers University, launched yesterday with $75m in series A capital co-led by Qiming Venture Partners and VenBio Partners, with commitments from pharmaceutical firm Bristol Myers Squibb, Perceptive Advisors’ Xontogeny Venture Fund, Janus Henderson, Affinity Asset Advisors, Boxer Capital and LifeSci Venture Partners. Ceptur had raised $6.2m in seed financing in August 2020, according to a regulatory filing, with Affinity Asset Advisors, Boxer Capital and LifeSci Venture Partners identified…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email Linked in